全球多形性膠質母細胞瘤治療市場 - 市場規模、佔有率、成長分析：按類型、按應用分類 - 產業預測（2023-2030）

Global Glioblastoma Multiforme Treatment Market Size, Share, Growth Analysis, By Type(Surgery, Radiation Therapy), By Application(Newly Diagnosed glioblastoma multiforme treatment, Recurrent glioblastoma multiforme treatment) - Industry Forecast 2023-2030

出版日期: 2023年10月24日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計2021年全球多形性膠質母細胞瘤治療市場規模將達23億美元，2022年將達25億美元。預計該市場在預測期（2023-2030年）將以8.9%的年複合成長率成長，到2030年將達到49.5億美元。

近年來，由於全球多形性膠質母細胞瘤治療病例數量的增加以及對有效治療方案的需求不斷成長，全球多形性膠質母細胞瘤治療市場出現了顯著成長。多形性膠質母細胞瘤的罹患率不斷增加，加上可用的治療選擇有限，迫切需要創新和有效的治療方法，從而推動市場成長。醫學研究和技術開發的進步正在促進治療多形性膠質母細胞瘤的新治療方法的開發。市場正在向個人化醫療方法轉變，重點是標靶治療和免疫療法。標靶治療，例如酪胺酸激酶抑制劑和單株抗體，旨在破壞多形性膠質母細胞瘤治療進展中涉及的特定分子途徑。免疫療法，包括免疫檢查點抑制劑和嵌合抗原受體（CAR）T細胞療法，利用人體的免疫系統來辨識並消滅癌細胞。這些進步顯著改善了治療結果，並推動了多形性膠質母細胞瘤治療市場的成長。

多形性膠質母細胞瘤（一種侵襲性腦瘤）發生率的增加是市場的關鍵驅動力。隨著全球多形性膠質母細胞瘤的盛行率持續上升，越來越需要開發有效的治療方案。這推動了對多形性膠質母細胞瘤治療的需求並推動市場成長。

治療多形性膠質母細胞瘤的費用是患者的經濟負擔，主要是由於與手術、放射線治療、化療和支持性護理相關的費用。高治療成本會阻礙患者獲得先進治療並影響治療的承受能力。此外，報銷政策在確定患者獲得治療的機會方面發揮關鍵作用，從而影響市場成長。

本報告研究了全球多形性膠質母細胞瘤治療市場，並提供了市場概述，包括按類型、應用、地區和參與市場的公司概況分類的趨勢。

主要企業簡介
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Bristol Myers Squibb Company
- Eli Lilly and Company
- AbbVie Inc.
- Pfizer Inc
- Tocagen Inc.
- Kazia Therapeutics Limited
- DelMar Pharmaceuticals, Inc.
- Arbor Pharmaceuticals, LLC
- BTG International Ltd
- Mundipharma International Limited
- Northwest Biotherapeutics
- Orbus Therapeutics Inc.
- VBL Therapeutics
- GT Medical Technologies, Inc.
- Oncolys Biopharma Inc.
- Tocagen
- ValiRx Plc

簡介目錄

Product Code: SQMIG35D2105

Global Glioblastoma Multiforme Treatment Market size was valued at USD 2.3 billion in 2021 and is poised to grow from USD 2.5 billion in 2022 to USD 4.95 billion by 2030, growing at a CAGR of 8.9% in the forecast period (2023-2030).

The global market for glioblastoma multiforme treatment has witnessed substantial growth in recent years, driven by the increasing incidence of glioblastoma multiforme treatment cases worldwide and the growing demand for effective treatment options. The increasing incidence of glioblastoma multiforme treatment, coupled with the limited treatment options available, has created a pressing need for innovative and effective therapies, thereby fueling market growth. Advancements in medical research and technology have contributed to the development of novel treatment modalities for glioblastoma multiforme treatment. The market has witnessed a shift towards personalised medicine approaches, with a focus on targeted therapies and immunotherapies. Targeted therapies, such as tyrosine kinase inhibitors and monoclonal antibodies, aim to disrupt specific molecular pathways involved in glioblastoma multiforme treatment progression. Immunotherapies, including immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, harness the body's immune system to recognize and destroy cancer cells. These advancements have significantly improved treatment outcomes and have spurred the growth of the glioblastoma multiforme treatment market.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Glioblastoma Multiforme Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glioblastoma Multiforme Treatment Market Segmental Analysis

The global glioblastoma multiforme treatment market is segmented by type, application, and region. Based on type, the market can be segmented into Surgery, Radiation Therapy, Chemotherapy and Targeted Therapy. Based on application, the market is segmented into Newly Diagnosed glioblastoma multiforme treatment, Recurrent glioblastoma multiforme treatment, Palliative Care, Clinical Trials and Paediatric glioblastoma multiforme treatment. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Glioblastoma Multiforme Treatment Market

Increasing Incidence of Glioblastoma Multiforme

The increasing occurrence of glioblastoma multiforme, an aggressive brain cancer, is a significant driver of the market. As the prevalence of glioblastoma multiforme treatment continues to rise worldwide, there is a growing need for the development of effective treatment options. This drives the demand for glioblastoma multiforme treatment treatments and fuels market growth.

Restraints in the Global Glioblastoma Multiforme Treatment Market

High Treatment Costs

The cost of glioblastoma multiforme treatment poses a financial burden for patients, primarily due to the expenses associated with surgery, radiation therapy, chemotherapy, and supportive care. The high treatment costs can impede patient access to advanced therapies and impact the affordability of treatments. Furthermore, reimbursement policies play a crucial role in determining patient access to these treatments, thereby influencing market growth.

Market Trends of Global Glioblastoma Multiforme Treatment Key

Increasing Use of Targeted Therapies: Targeted therapies are designed to target specific molecules involved in the growth and spread of glioblastoma multiforme treatment cells. These therapies have shown promise in improving the survival rates of patients with glioblastoma multiforme treatment.
Development of New Immunotherapies: Immunotherapies are designed to boost the body's immune system to fight cancer cells. These therapies are still in the early stages of development, but they have shown promise in treating glioblastoma multiforme treatment.
The Increasing Demand for Personalised treatment: Personalised treatment is tailored to the individual patient's tumour profile. This approach has the potential to improve the efficacy and safety of treatment for glioblastoma multiforme treatment patients.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Glioblastoma Multiforme Treatment Market by Type
- Market Overview
- Surgery
- Radiation Therapy
- Chemotherapy
- and Targeted Therapy.
Global Glioblastoma Multiforme Treatment Market by Application
- Market Overview
- Newly Diagnosed glioblastoma multiforme treatment
- Recurrent glioblastoma multiforme treatment
- Palliative Care
- Clinical Trials and Pediatric glioblastoma multiforme treatment.
Global Glioblastoma Multiforme Treatment Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Merck & Co., Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- F. Hoffmann-La Roche Ltd (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Novartis AG (Switzerland)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bristol Myers Squibb Company (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Eli Lilly and Company (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- AbbVie Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Pfizer Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Tocagen Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Kazia Therapeutics Limited (Australia)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- DelMar Pharmaceuticals, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Arbor Pharmaceuticals, LLC (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- BTG International Ltd (United Kingdom)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Mundipharma International Limited (United Kingdom)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Northwest Biotherapeutics (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Orbus Therapeutics Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- VBL Therapeutics (Israel)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- GT Medical Technologies, Inc. (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Oncolys Biopharma Inc. (Japan)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Tocagen (US)
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- ValiRx Plc (United Kingdom)
Company Overview
Business Segment Overview
Financial Updates
Key Developments